top of page
LATEST NEWS
Four Years After One Infusion, a Gene Therapy Keeps Crigler-Najjar Syndrome in Check
In NEJM, Généthon's AAV gene therapy GNT0003 kept bilirubin below toxic levels for four years in all three patients at the therapeutic dose, and two stopped daily phototherapy.
3 hours ago3 min read


Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
1 day ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
2 days ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Four Years After One Infusion, a Gene Therapy Keeps Crigler-Najjar Syndrome in Check
In NEJM, Généthon's AAV gene therapy GNT0003 kept bilirubin below toxic levels for four years in all three patients at the therapeutic dose, and two stopped daily phototherapy.
3 hours ago


Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
1 day ago


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
2 days ago


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
2 days ago


Gene Therapy for Huntington's Disease: Everything We've Covered
uniQure's AMT-130 is the first Huntington's gene therapy to reach the FDA with long-term data behind it. Every Gene Tech Times story on it, in order, with what to watch before the May 2027 decision.
2 days ago
bottom of page


